Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT/ASCT) + peripheral blood lymphocyte (PBL) reinfusion.

Alexander M. Lesokhin,David J. Chung,Hearn Jay Cho,Lisa Shohara,Paul Schwarzenberger,Toni Ricciardi,Mary J. Macri,Aileen Ryan,Ralph Venhaus

Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT/ASCT) + peripheral blood lymphocyte (PBL) reinfusion.

2017

Alexander M. Lesokhin
David J. Chung
Hearn Jay Cho
Lisa Shohara
Paul Schwarzenberger
Toni Ricciardi
Mary J. Macri
Aileen Ryan
Ralph Venhaus

TPS8051Background: Multiple myeloma (MM) remains an incurable hematologic malignancy despite the advent of new classes of drugs, including immunomodulatory agents, proteasome inhibitors, and monocl...

Keywords:

Stem cell
Pathology
Peripheral blood lymphocyte
Immunotherapy
Durvalumab
Cancer research
Chemotherapy
Medicine
Multiple myeloma
Tremelimumab
Hematologic malignancy
Oncology
Internal medicine
high dose chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations